Adds Chicago research and development facility, New Jersey manufacturing site
WASHINGTON (August 21, 2026) — The Association for Accessible Medicines today commented on the announcement by Amneal Pharmaceuticals, Inc. of the completion of their acquisition of U.S. based Kashiv BioSciences, which creates a fully end-to-end biosimilars capacity, from research, development, manufacturing, and commercialization.
“Amneal’s investment to expand domestic development and manufacturing of biosimilars in the U.S. directly aligns with the President’s efforts to strengthen our domestic supply chain for critical medicines, and provides lower-cost medicines to Americans,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “AAM has been shining a light on the ‘biosimilar void’ or the lack of current development for biologic medicines coming off patent in the next ten years. This will directly help create competition and lower costs for patients and the overall healthcare ecosystem.”
With this acquisition, Amneal will have two facilities with over 150,000 square feet in New Jersey as well as a 100,000 square foot R&D and manufacturing facility in Chicago.
Amneal joins fellow AAM members in their commitment to domestic manufacturing and U.S. investment. Last year, Hikma announced the groundbreaking of a new facility in Ohio and expansion of facilities in Ohio and New Jersey. Amphastar announced an expansion of its California facilities that will quadruple their production within five years. Lupin announced investments of $250 million to build a new manufacturing facility in Florida.
AAM Release on Lupin Announcement
AAM Release on Amphastar announcement
AAM Release on Hikma Announcement
U.S. Generic & Biosimilar Medicines Savings Report
Media contact: media@accessiblemeds.org
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 12 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at www.biosimilarscouncil.org.
